Bladder Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：222頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Bladder Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Bladder Cancer - Pipeline Review, H1 2014’, provides an overview of the Bladder Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Bladder Cancer - Pipeline Review, H1 2014’, provides an overview of the Bladder Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bladder Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Bladder Cancer - Overview 11
Pipeline Products for Bladder Cancer - Comparative Analysis 12
Bladder Cancer - Therapeutics under Development by Companies 13
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 18
Bladder Cancer - Pipeline Products Glance 20
Clinical Stage Products 20
Early Stage Products 21
Bladder Cancer - Products under Development by Companies 22
Bladder Cancer - Products under Investigation by Universities/Institutes 25
Bladder Cancer - Companies Involved in Therapeutics Development 26
Shionogi & Co., Ltd. 26
AstraZeneca PLC 27
Eli Lilly and Company 28
Viralytics Ltd. 29
GlaxoSmithKline plc 30
Bioniche Life Sciences, Inc. 31
Biotest AG 32
Samyang Holdings Corporation 33
Astellas Pharma Inc. 34
Eisai Co., Ltd. 35
Marina Biotech, Inc. 36
Taiho Pharmaceutical Co., Ltd. 37
Celgene Corporation 38
Advaxis, Inc. 39
Evotec AG 40
Immunomedics, Inc. 41
Alnylam Pharmaceuticals, Inc. 42
Oncogenex Pharmaceuticals, Inc. 43
Dendreon Corporation 44
Sanochemia Pharmazeutika AG 45
Quest PharmaTech Inc. 46
Med Discovery SA 47
Hutchison MediPharma Limited 48
Altor BioScience Corporation 49
Telormedix SA 50
Gene Signal International SA 51
MacroGenics, Inc. 52
Innate Therapeutics Limited 53
Stemline Therapeutics, Inc. 54
BioCancell Therapeutics, Inc. 55
AndroScience Corporation 56
Pharma Mar, S.A. 57
NuCana BioMed Limited 58
Polaris Group 59
Serometrix, LLC 60
Regulon Inc. 61
SentoClone International AB 62
Optimum Therapeutics, LLC 63
Lipella Pharmaceuticals, Inc. 64
APIM Therapeutics AS 65
Qu Biologics Inc. 66
Panacela Labs, Inc. 67
Oncopeptides AB 68
DormaTarg, Inc. 69
AlphaMab Co., Ltd 70
Bladder Cancer - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 77
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 86
apatorsen - Drug Profile 86
paclitaxel-loaded polymeric micelle - Drug Profile 88
paclitaxel albumin-bound - Drug Profile 90
ramucirumab - Drug Profile 92
ALT-801 - Drug Profile 96
BC-819 - Drug Profile 98
lapuleucel-t - Drug Profile 100
PM-00104 - Drug Profile 101
SentoClone - Drug Profile 102
recMAGE-A3 + AS15 - Drug Profile 104
IMMU-132 - Drug Profile 105
eribulin mesylate - Drug Profile 106
S-288310 - Drug Profile 110
CVA-21 - Drug Profile 111
PVP Hypericin - Drug Profile 115
AZD-4547 - Drug Profile 116
margetuximab - Drug Profile 117
NUC-1031 - Drug Profile 119
ASG-15-ME - Drug Profile 121
GSK-2849330 - Drug Profile 122
MDRG-01 - Drug Profile 123
MDP-01 - Drug Profile 124
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 125
SL-601 - Drug Profile 126
BT-062 - Drug Profile 127
TMX-202 - Drug Profile 129
BC-821 - Drug Profile 130
MDR-09521 - Drug Profile 131
SL-052 - Drug Profile 132
MRNA-046 - Drug Profile 134
aganirsen - Drug Profile 135
pegargiminase - Drug Profile 137
cisplatin liposomal - Drug Profile 140
MIS-416 - Drug Profile 142
Revercom - Drug Profile 144
Mobilan - Drug Profile 145
ASC-JM.Z1 - Drug Profile 146
ATX-101 - Drug Profile 147
LNP-dsP21-322-2'F - Drug Profile 148
TAS-2985 - Drug Profile 149
Melflufen - Drug Profile 150
DT-310 - Drug Profile 152
DT-320 - Drug Profile 153
DT-330 - Drug Profile 154
nitroxoline - Drug Profile 155
Diphtheria Toxin Epidermal Growth Factor Fusion Protein - Drug Profile 156
Antibodies For N-cadherin - Drug Profile 157
ICT-2700 - Drug Profile 158
Lm-LLO-ISG-15 - Drug Profile 159
FGFR Program - Drug Profile 161
BV-2711 - Drug Profile 162
suramin hexasodium - Drug Profile 163
SX-MTR1 - Drug Profile 165
QBECP SSI - Drug Profile 166
KN-014 - Drug Profile 167
EMMPRIN-Conjugates - Drug Profile 168
Drug for Bladder Cancer - Drug Profile 169
MDNA-55 - Drug Profile 170
Drugs to Inhibit FGFR3 for Cancer - Drug Profile 171
Bladder Cancer - Recent Pipeline Updates 172
Bladder Cancer - Dormant Projects 206
Bladder Cancer - Discontinued Products 208
Bladder Cancer - Product Development Milestones 209
Featured News & Press Releases 209
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218
List of Tables
Number of Products under Development for Bladder Cancer, H1 2014 15
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Development by Companies, H1 2014 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2014 29
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H1 2014 30
Bladder Cancer - Pipeline by AstraZeneca PLC, H1 2014 31
Bladder Cancer - Pipeline by Eli Lilly and Company, H1 2014 32
Bladder Cancer - Pipeline by Viralytics Ltd., H1 2014 33
Bladder Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 34
Bladder Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014 35
Bladder Cancer - Pipeline by Biotest AG, H1 2014 36
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 37
Bladder Cancer - Pipeline by Astellas Pharma Inc., H1 2014 38
Bladder Cancer - Pipeline by Eisai Co., Ltd., H1 2014 39
Bladder Cancer - Pipeline by Marina Biotech, Inc., H1 2014 40
Bladder Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 41
Bladder Cancer - Pipeline by Celgene Corporation, H1 2014 42
Bladder Cancer - Pipeline by Advaxis, Inc., H1 2014 43
Bladder Cancer - Pipeline by Evotec AG, H1 2014 44
Bladder Cancer - Pipeline by Immunomedics, Inc., H1 2014 45
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 46
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 47
Bladder Cancer - Pipeline by Dendreon Corporation, H1 2014 48
Bladder Cancer - Pipeline by Sanochemia Pharmazeutika AG, H1 2014 49
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H1 2014 50
Bladder Cancer - Pipeline by Med Discovery SA, H1 2014 51
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 52
Bladder Cancer - Pipeline by Altor BioScience Corporation, H1 2014 53
Bladder Cancer - Pipeline by Telormedix SA, H1 2014 54
Bladder Cancer - Pipeline by Gene Signal International SA, H1 2014 55
Bladder Cancer - Pipeline by MacroGenics, Inc., H1 2014 56
Bladder Cancer - Pipeline by Innate Therapeutics Limited, H1 2014 57
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 58
Bladder Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2014 59
Bladder Cancer - Pipeline by AndroScience Corporation, H1 2014 60
Bladder Cancer - Pipeline by Pharma Mar, S.A., H1 2014 61
Bladder Cancer - Pipeline by NuCana BioMed Limited, H1 2014 62
Bladder Cancer - Pipeline by Polaris Group, H1 2014 63
Bladder Cancer - Pipeline by Serometrix, LLC, H1 2014 64
Bladder Cancer - Pipeline by Regulon Inc., H1 2014 65
Bladder Cancer - Pipeline by SentoClone International AB, H1 2014 66
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2014 67
Bladder Cancer - Pipeline by Lipella Pharmaceuticals, Inc., H1 2014 68
Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2014 69
Bladder Cancer - Pipeline by Qu Biologics Inc., H1 2014 70
Bladder Cancer - Pipeline by Panacela Labs, Inc., H1 2014 71
Bladder Cancer - Pipeline by Oncopeptides AB, H1 2014 72
Bladder Cancer - Pipeline by DormaTarg, Inc., H1 2014 73
Bladder Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 74
Assessment by Monotherapy Products, H1 2014 75
Assessment by Combination Products, H1 2014 76
Number of Products by Stage and Target, H1 2014 79
Number of Products by Stage and Mechanism of Action, H1 2014 83
Number of Products by Stage and Route of Administration, H1 2014 86
Number of Products by Stage and Molecule Type, H1 2014 89
Bladder Cancer Therapeutics - Recent Pipeline Updates, H1 2014 176
Bladder Cancer - Dormant Projects, H1 2014 210
Bladder Cancer - Dormant Projects (Contd..1), H1 2014 211
Bladder Cancer - Discontinued Products, H1 2014 212
List of Figures
Number of Products under Development for Bladder Cancer, H1 2014 15
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 75
Number of Products by Top 10 Target, H1 2014 77
Number of Products by Stage and Top 10 Target, H1 2014 78
Number of Products by Top 10 Mechanism of Action, H1 2014 81
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 82
Number of Products by Top 10 Route of Administration, H1 2014 85
Number of Products by Stage and Top 10 Route of Administration, H1 2014 86
Number of Products by Top 10 Molecule Type, H1 2014 87
Number of Products by Stage and Top 10 Molecule Type, H1 2014 88
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bladder Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Bladder Cancer - Overview 11
Pipeline Products for Bladder Cancer - Comparative Analysis 12
Bladder Cancer - Therapeutics under Development by Companies 13
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 18
Bladder Cancer - Pipeline Products Glance 20
Clinical Stage Products 20
Early Stage Products 21
Bladder Cancer - Products under Development by Companies 22
Bladder Cancer - Products under Investigation by Universities/Institutes 25
Bladder Cancer - Companies Involved in Therapeutics Development 26
Shionogi & Co., Ltd. 26
AstraZeneca PLC 27
Eli Lilly and Company 28
Viralytics Ltd. 29
GlaxoSmithKline plc 30
Bioniche Life Sciences, Inc. 31
Biotest AG 32
Samyang Holdings Corporation 33
Astellas Pharma Inc. 34
Eisai Co., Ltd. 35
Marina Biotech, Inc. 36
Taiho Pharmaceutical Co., Ltd. 37
Celgene Corporation 38
Advaxis, Inc. 39
Evotec AG 40
Immunomedics, Inc. 41
Alnylam Pharmaceuticals, Inc. 42
Oncogenex Pharmaceuticals, Inc. 43
Dendreon Corporation 44
Sanochemia Pharmazeutika AG 45
Quest PharmaTech Inc. 46
Med Discovery SA 47
Hutchison MediPharma Limited 48
Altor BioScience Corporation 49
Telormedix SA 50
Gene Signal International SA 51
MacroGenics, Inc. 52
Innate Therapeutics Limited 53
Stemline Therapeutics, Inc. 54
BioCancell Therapeutics, Inc. 55
AndroScience Corporation 56
Pharma Mar, S.A. 57
NuCana BioMed Limited 58
Polaris Group 59
Serometrix, LLC 60
Regulon Inc. 61
SentoClone International AB 62
Optimum Therapeutics, LLC 63
Lipella Pharmaceuticals, Inc. 64
APIM Therapeutics AS 65
Qu Biologics Inc. 66
Panacela Labs, Inc. 67
Oncopeptides AB 68
DormaTarg, Inc. 69
AlphaMab Co., Ltd 70
Bladder Cancer - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 77
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 86
apatorsen - Drug Profile 86
paclitaxel-loaded polymeric micelle - Drug Profile 88
paclitaxel albumin-bound - Drug Profile 90
ramucirumab - Drug Profile 92
ALT-801 - Drug Profile 96
BC-819 - Drug Profile 98
lapuleucel-t - Drug Profile 100
PM-00104 - Drug Profile 101
SentoClone - Drug Profile 102
recMAGE-A3 + AS15 - Drug Profile 104
IMMU-132 - Drug Profile 105
eribulin mesylate - Drug Profile 106
S-288310 - Drug Profile 110
CVA-21 - Drug Profile 111
PVP Hypericin - Drug Profile 115
AZD-4547 - Drug Profile 116
margetuximab - Drug Profile 117
NUC-1031 - Drug Profile 119
ASG-15-ME - Drug Profile 121
GSK-2849330 - Drug Profile 122
MDRG-01 - Drug Profile 123
MDP-01 - Drug Profile 124
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 125
SL-601 - Drug Profile 126
BT-062 - Drug Profile 127
TMX-202 - Drug Profile 129
BC-821 - Drug Profile 130
MDR-09521 - Drug Profile 131
SL-052 - Drug Profile 132
MRNA-046 - Drug Profile 134
aganirsen - Drug Profile 135
pegargiminase - Drug Profile 137
cisplatin liposomal - Drug Profile 140
MIS-416 - Drug Profile 142
Revercom - Drug Profile 144
Mobilan - Drug Profile 145
ASC-JM.Z1 - Drug Profile 146
ATX-101 - Drug Profile 147
LNP-dsP21-322-2'F - Drug Profile 148
TAS-2985 - Drug Profile 149
Melflufen - Drug Profile 150
DT-310 - Drug Profile 152
DT-320 - Drug Profile 153
DT-330 - Drug Profile 154
nitroxoline - Drug Profile 155
Diphtheria Toxin Epidermal Growth Factor Fusion Protein - Drug Profile 156
Antibodies For N-cadherin - Drug Profile 157
ICT-2700 - Drug Profile 158
Lm-LLO-ISG-15 - Drug Profile 159
FGFR Program - Drug Profile 161
BV-2711 - Drug Profile 162
suramin hexasodium - Drug Profile 163
SX-MTR1 - Drug Profile 165
QBECP SSI - Drug Profile 166
KN-014 - Drug Profile 167
EMMPRIN-Conjugates - Drug Profile 168
Drug for Bladder Cancer - Drug Profile 169
MDNA-55 - Drug Profile 170
Drugs to Inhibit FGFR3 for Cancer - Drug Profile 171
Bladder Cancer - Recent Pipeline Updates 172
Bladder Cancer - Dormant Projects 206
Bladder Cancer - Discontinued Products 208
Bladder Cancer - Product Development Milestones 209
Featured News & Press Releases 209
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218
List of Tables
Number of Products under Development for Bladder Cancer, H1 2014 15
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Development by Companies, H1 2014 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2014 29
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H1 2014 30
Bladder Cancer - Pipeline by AstraZeneca PLC, H1 2014 31
Bladder Cancer - Pipeline by Eli Lilly and Company, H1 2014 32
Bladder Cancer - Pipeline by Viralytics Ltd., H1 2014 33
Bladder Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 34
Bladder Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014 35
Bladder Cancer - Pipeline by Biotest AG, H1 2014 36
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 37
Bladder Cancer - Pipeline by Astellas Pharma Inc., H1 2014 38
Bladder Cancer - Pipeline by Eisai Co., Ltd., H1 2014 39
Bladder Cancer - Pipeline by Marina Biotech, Inc., H1 2014 40
Bladder Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 41
Bladder Cancer - Pipeline by Celgene Corporation, H1 2014 42
Bladder Cancer - Pipeline by Advaxis, Inc., H1 2014 43
Bladder Cancer - Pipeline by Evotec AG, H1 2014 44
Bladder Cancer - Pipeline by Immunomedics, Inc., H1 2014 45
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 46
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 47
Bladder Cancer - Pipeline by Dendreon Corporation, H1 2014 48
Bladder Cancer - Pipeline by Sanochemia Pharmazeutika AG, H1 2014 49
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H1 2014 50
Bladder Cancer - Pipeline by Med Discovery SA, H1 2014 51
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 52
Bladder Cancer - Pipeline by Altor BioScience Corporation, H1 2014 53
Bladder Cancer - Pipeline by Telormedix SA, H1 2014 54
Bladder Cancer - Pipeline by Gene Signal International SA, H1 2014 55
Bladder Cancer - Pipeline by MacroGenics, Inc., H1 2014 56
Bladder Cancer - Pipeline by Innate Therapeutics Limited, H1 2014 57
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 58
Bladder Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2014 59
Bladder Cancer - Pipeline by AndroScience Corporation, H1 2014 60
Bladder Cancer - Pipeline by Pharma Mar, S.A., H1 2014 61
Bladder Cancer - Pipeline by NuCana BioMed Limited, H1 2014 62
Bladder Cancer - Pipeline by Polaris Group, H1 2014 63
Bladder Cancer - Pipeline by Serometrix, LLC, H1 2014 64
Bladder Cancer - Pipeline by Regulon Inc., H1 2014 65
Bladder Cancer - Pipeline by SentoClone International AB, H1 2014 66
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2014 67
Bladder Cancer - Pipeline by Lipella Pharmaceuticals, Inc., H1 2014 68
Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2014 69
Bladder Cancer - Pipeline by Qu Biologics Inc., H1 2014 70
Bladder Cancer - Pipeline by Panacela Labs, Inc., H1 2014 71
Bladder Cancer - Pipeline by Oncopeptides AB, H1 2014 72
Bladder Cancer - Pipeline by DormaTarg, Inc., H1 2014 73
Bladder Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 74
Assessment by Monotherapy Products, H1 2014 75
Assessment by Combination Products, H1 2014 76
Number of Products by Stage and Target, H1 2014 79
Number of Products by Stage and Mechanism of Action, H1 2014 83
Number of Products by Stage and Route of Administration, H1 2014 86
Number of Products by Stage and Molecule Type, H1 2014 89
Bladder Cancer Therapeutics - Recent Pipeline Updates, H1 2014 176
Bladder Cancer - Dormant Projects, H1 2014 210
Bladder Cancer - Dormant Projects (Contd..1), H1 2014 211
Bladder Cancer - Discontinued Products, H1 2014 212
List of Figures
Number of Products under Development for Bladder Cancer, H1 2014 15
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 75
Number of Products by Top 10 Target, H1 2014 77
Number of Products by Stage and Top 10 Target, H1 2014 78
Number of Products by Top 10 Mechanism of Action, H1 2014 81
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 82
Number of Products by Top 10 Route of Administration, H1 2014 85
Number of Products by Stage and Top 10 Route of Administration, H1 2014 86
Number of Products by Top 10 Molecule Type, H1 2014 87
Number of Products by Stage and Top 10 Molecule Type, H1 2014 88
